|
KMID : 0620920230550050926
|
|
Experimental & Molecular Medicine
2023 Volume.55 No. 5 p.926 ~ p.938
|
|
|
The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy
|
|
Nick Ossei-Gerning
Jeff Foster
Leong-Perng Chan
Chun-Chieh Wu
Jeng-Shiun Du
Pei-Lin Liu
Meng-Chun Chou
Che-Wei Wu
Chih-Jen Huang
Hui-Hua Hsiao
Mei-Ren Pan
Li-Tzong Chen
|
|
|
Abstract
|
|
|
|
Personalized genetic profiling has focused on improving treatment efficacy and predicting risk stratification by identifying mutated genes and selecting targeted agents according to genetic testing. Therefore, we evaluated the role of genetic profiling and tumor mutation burden (TMB) using next-generation sequencing in patients with head and neck squamous cell carcinoma (HNSC). The relapse mutation signature (RMS) and chromatin remodeling mutation signature (CRMS) were explored to predict the risk of relapse in patients with HNSC treated with concurrent chemoradiotherapy (CCRT) with platinum-based chemotherapy. Patients in the high RMS and CRMS groups showed significantly shorter relapse-free survival than those in the low RMS and CRMS groups, respectively (p?
|
|
|
KEYWORD
|
|
|
Genome-wide association studies, Oral cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|